Richard M. Eglen

Richard M. Eglen's AcademicInfluence.com Rankings

Richard M. Eglen

Medical

#2846

World Rank

#3287

Historical Rank

Pharmacology

#321

World Rank

#372

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Richard M. Eglen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard M. Eglen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Muscarinic receptor subtypes and smooth muscle function. (1996) (576)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development (2007) (569)
Structure and Function of a Novel Voltage-gated, Tetrodotoxin-resistant Sodium Channel Specific to Sensory Neurons (*) (1996) (429)
Distribution of the Tetrodotoxin-Resistant Sodium Channel PN3 in Rat Sensory Neurons in Normal and Neuropathic Conditions (1998) (388)
A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. (1999) (321)
Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo (1997) (319)
Assessment of the role of α2‐adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice (1997) (312)
A Novel Tetrodotoxin-sensitive, Voltage-gated Sodium Channel Expressed in Rat and Human Dorsal Root Ganglia* (1997) (280)
Three-Dimensional Cell Cultures in Drug Discovery and Development (2017) (277)
RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist (1997) (270)
Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. (2006) (270)
Three-Dimensional Cell Cultures in Drug Discovery and Development. (2017) (264)
Muscarinic acetylcholine receptor subtypes in smooth muscle. (1994) (257)
'Seeing through a glass darkly': casting light on imidazoline 'I' sites. (1998) (247)
Central 5-HT4 receptors. (1995) (227)
Immunocytochemical localization of P2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury (1999) (226)
The role of IP prostanoid receptors in inflammatory pain. (1998) (211)
Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. (1999) (208)
The Use of AlphaScreen Technology in HTS: Current Status (2008) (206)
5‐Hydroxytryptamine (5‐HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases (1995) (201)
Muscarinic receptor subtype pharmacology and physiology. (2005) (192)
Cloning and Expression of a 5‐Hydroxytryptamine7 Receptor Positively Coupled to Adenylyl Cyclase (1994) (181)
Muscarinic receptor subtypes: a critique of the current classification and a proposal for a working nomenclature. (1986) (179)
Peripheral 5‐HT4 receptors (1996) (176)
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro (1995) (176)
The 5-HT7 receptor: orphan found. (1997) (171)
Therapeutic opportunities from muscarinic receptor research. (2001) (165)
Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. (1995) (159)
Ligand Efficacy and Potency at Recombinant α2 Adrenergic Receptors: Agonist-Mediated [35s]gtpγs Binding (1998) (136)
Selective muscarinic receptor agonists and antagonists. (1996) (135)
Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. (1995) (131)
7TM receptors: the splicing on the cake. (1999) (130)
Characterization of 5‐HT3 and ‘atypical’ 5‐HT receptors mediating guinea‐pig ileal contractions in vitro (1990) (124)
Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. (1995) (123)
The muscarinic M5 receptor: a silent or emerging subtype? (2000) (123)
Functional Analysis of a Voltage‐Gated Sodium Channel and Its Splice Variant from Rat Dorsal Root Ganglia (1998) (122)
Cloning, expression and pharmacology of a truncated splice variant of the human 5‐HT7 receptor (h5‐HT7(b)) (1997) (121)
Increased acid-sensing ion channel ASIC-3 in inflamed human intestine (2001) (118)
The Effects of Novel, Selective 5-Hydroxytryptamine (5-HT)4 Receptor Ligands in Rat Spatial Navigation (1997) (107)
Muscarinic receptor ligands and their therapeutic potential. (1999) (102)
Ions in the fire: recent ion-channel research and approaches to pain therapy. (1999) (99)
The pharmacological properties of the peptide, endothelin (1989) (98)
Heterogeneity of vascular muscarinic receptors. (1990) (95)
A tetrodotoxin-resistant voltage-gated sodium channel from human dorsal root ganglia, hPN3/SCN10A (1998) (94)
Muscarinic receptors and gastrointestinal tract smooth muscle function. (2001) (93)
Differential distribution of the tetrodotoxin‐sensitive rPN4/NaCh6/Scn8a sodium channel in the nervous system (2000) (92)
Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1 (1994) (91)
Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. (2007) (90)
The current status of drug discovery against the human kinome. (2009) (88)
Characterization of prostanoid receptor‐evoked responses in rat sensory neurones (1998) (88)
Molecular cloning, genomic characterization and expression of novel human α1A‐adrenoceptor isoforms (1998) (87)
Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. (1999) (87)
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. (1993) (87)
Enzyme fragment complementation: a flexible high throughput screening assay technology. (2002) (86)
Pharmacological characterization of two novel and potent 5‐HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo (1995) (86)
Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. (1995) (86)
Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening. (2011) (81)
In vitroα1‐adrenoceptor pharmacology of Ro 70–0004 and RS‐100329, novel α1A‐adrenoceptor selective antagonists (1999) (78)
Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017 (1998) (77)
Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. (2007) (76)
Regulation of Glial Cell Line‐Derived Neurotrophic Factor Release from Rat C6 Glioblastoma Cells (1998) (75)
Overview of muscarinic receptor subtypes. (2012) (75)
Effects of cannabinoid receptor agonists on neuronally‐evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human (2000) (72)
Characterization of putative 5‐ht7 receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein (1996) (70)
Drug discovery and the human kinome: recent trends. (2011) (70)
The interaction of parafluorohexahydrosiladiphenidol at muscarinic receptors in vitro (1990) (69)
Regulation of Na+ channel distribution in the nervous system (2001) (68)
Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild‐type and D79N α2A‐adrenoceptor transgenic mice (1999) (68)
The structure and signalling properties of 5-HT receptors: an endless diversity? (1998) (67)
The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety. (1993) (67)
Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. (1999) (67)
Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders (1995) (66)
Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening? (2015) (66)
A Generic, Homogenous Method for Measuring Kinase and Inhibitor Activity via Adenosine 5′-Diphosphate Accumulation (2006) (65)
SNS/PN3 and SNS2/NaN sodium channel‐like immunoreactivity in human adult and neonate injured sensory nerves (2000) (65)
Characterization of the muscarinic receptor subtype mediating contractions of the guinea‐pig uterus (1989) (59)
RS 39604: a potent, selective and orally active 5‐HT4 receptor antagonist (1995) (58)
Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle (1998) (57)
The action of SDZ 205,557 at 5‐hydroxytryptamine (5‐HT3 and 5‐HT4) receptors (1993) (55)
Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist. (1995) (53)
The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets (1988) (53)
Gene Substitution/Knockout to Delineate the Role of α2‐Adrenoceptor Subtypes in Mediating Central Effects of Catecholamines and Imidazolines (1999) (53)
5-Hydroxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT4 receptors. (1992) (53)
[3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. (1993) (52)
Evidence for the involvement of 5-hydroxytryptamine 4 receptors in 5-hydroxytryptophan-induced diarrhea in mice. (1994) (51)
P2X3 receptor in injured human sensory neurons (2000) (51)
Pharmacological Characterization of 5‐Hydroxytryptamine3Receptors in Murine Brain and Ileum Using the Novel Radioligand [3H]RS‐42358–197: Evidence for Receptor Heterogeneity (1993) (50)
Selective inactivation of muscarinic M2 and M3 receptors in guinea‐pig ileum and atria in vitro (1993) (48)
Pharmacological properties of 5-Hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors. (2000) (47)
Comparison of the muscarinic receptors of the guinea-pig oesophageal muscularis mucosae and trachea in vitro. (1988) (46)
Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol. (1990) (45)
Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. (1998) (45)
Ondansetron improves cognitive performance in the Morris water maze spatial navigation task (1995) (45)
Beta galactosidase enzyme fragment complementation as a novel technology for high throughput screening. (2003) (44)
EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. (1990) (44)
Determination of the muscarinic receptor subtype mediating vasodilatation. (1985) (43)
Characterization of a promoter for the human glial cell line-derived neurotrophic factor gene. (1999) (42)
Characterization of α2‐adrenoceptors mediating contraction of dog saphenous vein: identity with the human α2A subtype (1997) (41)
Muscarinic Receptor Subtypes in Smooth Muscle (1997) (41)
Selective inactivation of muscarinic receptor subtypes. (1994) (41)
Functional G protein-coupled receptor assays for primary and secondary screening. (2005) (41)
5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum (1990) (40)
Negative and positive inotropic responses to muscarinic agonists in guinea pig and rat atria in vitro. (1988) (39)
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). (1997) (38)
Harmane and harmalan are bioactive components of classical clonidine-displacing substance. (2004) (37)
The use of immortalized cell lines in GPCR screening: the good, bad and ugly. (2008) (36)
Evidence for purinergic neurotransmission in the urinary bladder of pithed rats. (1998) (36)
Photoproteins: important new tools in drug discovery. (2008) (34)
A High-Throughput, Nonisotopic, Competitive Binding Assay for Kinases Using Nonselective Inhibitor Probes (ED-NSIP™) (2002) (33)
Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro (1989) (32)
Galactosidase Enzyme Fragment Complementation as a High-Throughput Screening Protease Technology (2004) (30)
An overview of drug screening using primary and embryonic stem cells. (2008) (29)
Analysis of concentration-response relationships by seemingly unrelated nonlinear regression (SUNR) technique. (1992) (29)
Acetylpromazine administration: its effect on canine haematology (1979) (28)
New insights into GPCR function: implications for HTS. (2009) (28)
RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo. (1993) (27)
Characterization of 5-hydroxytryptamine-induced depolarizations in rat isolated vagus nerve. (1994) (26)
Analysis of muscarinic cholinoceptors mediating phosphoinositide hydrolysis in guinea pig cardiac muscle. (1992) (25)
Characterization of the muscarinic receptor in isolated uterus of sham operated and ovariectomized rats (1999) (25)
Emerging concepts in GPCR function--the influence of cell phenotype on GPCR pharmacology. (2005) (24)
Role of muscarinic M2 and M3 receptors in guinea-pig trachea: effects of receptor alkylation. (1995) (23)
A homogeneous cell-based assay to measure nuclear translocation using beta-galactosidase enzyme fragment complementation. (2006) (22)
In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. (1999) (22)
Different densities of 5-HT3 receptors are labeled by [3H]quipazine, [3H]GR 65630 and [3H]geanisetron (1993) (22)
Leading Article: Central & Peripheral Nervous Systems: 5-Hydroxytryptamine (5-HT)4 receptors: physiology, pharmacology and therapeutic potential (1996) (21)
Acute desensitization of muscarinic receptors in the isolated guinea-pig ileal longitudinal muscle. (1992) (21)
Screening for Compounds That Modulate Epigenetic Regulation of the Transcriptome (2011) (20)
(R) and (S) RS 56532: Mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity (1994) (20)
Human kinome drug discovery and the emerging importance of atypical allosteric inhibitors (2010) (20)
Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometry (2001) (20)
Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 2: Spheroids, Organoids, and Disease Modeling (2019) (20)
Rs-100235: A high affinity 5-HT4 receptor antagonist (1995) (19)
Characterization of the interaction of zamifenacin at muscarinic receptors in vitro. (1995) (19)
[3H]RS-23597-190, a potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not sigma-2 binding sites in guinea pig brain. (1994) (19)
Muscarinic receptors subtypes: problems of classification (1985) (19)
5-HT4 Receptors in the Brain and Periphery (2013) (19)
Three-Dimensional Cell Culture Assays: Are They More Predictive of In Vivo Efficacy than 2D Monolayer Cell-Based Assays? (2015) (18)
GPCRs Revisited: New Insights Lead to Novel Drugs (2011) (18)
The 5‐HT3 receptor antagonist, RS‐56812, enhances delayed matching performance in monkeys (1996) (17)
Characterization of muscarinic receptor and beta-adrenoceptor interactions in guinea-pig oesophageal muscularis mucosae. (1995) (17)
Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse (1994) (17)
Using Ligand-Induced Conformational Change to Screen for Compounds Targeting G-Protein-Coupled Receptors (2007) (17)
N-(quinuclidin-3-YL)-1,8,-naphthalimides with 5-HT3 receptor antagonist and 5-HT4 receptor agonist properties (1993) (16)
5-Hydroxytryptamine (5-HT)4 receptors and central nervous system function: an update. (1997) (16)
Characterization of angiotensin II receptors in smooth muscle preparations of the guinea pig in vitro. (1993) (16)
Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists (1996) (16)
Homogeneous Assays for Cellular Protein Degradation Using β-Galactosidase Complementation: NF-κB/IκB Pathway Signaling (2003) (15)
Characterization of the interaction of the cervane alkaloid, imperialine, at muscarinic receptors in vitro (1992) (15)
5-HT3 receptor ligands lack modulatory influence on acetycholine release in rat entorhinal cortex (1993) (15)
Estimation of apparent agonist affinity constants using desensitization of the ileal muscarinic receptor. (1987) (15)
SYNTHESIS AND PRELIMINARY PHARMACOLOGICAL EVALUATION OF 2-BENZYLOXY SUBSTITUTED ARYL KETONES AS 5-HT4 RECEPTOR ANTAGONISTS (1994) (14)
Characterization of the m4 muscarinic receptor Ca2+ response in a subclone of PC-12 cells by single cell flow cytometry. Inhibition of the response by bradykinin. (1991) (14)
Differential effects of pertussis toxin on muscarinic responses in isolated atria and smooth muscle. (1988) (14)
Characterization of an atypical muscarinic cholinoceptor mediating contraction of the guinea‐pig isolated uterus (1998) (14)
Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats (1996) (14)
Ketones related to the benzoate 5-HT4 receptor antagonist RS-23597 are high affinity partial agonists (1994) (14)
Cardiovascular effects of R-alpha-methylhistamine, a selective histamine H3 receptor agonist, in rats: lack of involvement of histamine H3 receptors. (1994) (13)
Muscarinic M3 receptors mediate total inositol phosphates accumulation in murine HSDM1C1 fibrosarcoma cells. (1993) (13)
An Overview of High Throughput Screening at G Protein Coupled Receptors (2005) (13)
Conference on Advances in Serotonin Receptor Research (1998) (12)
Extraction of active clonidine-displacing substance from bovine lung and comparison with clonidine-displacing substance extracted from other tissues. (1999) (12)
High‐Throughput Screening and Virtual Screening: Entry Points to Drug Discovery (2000) (12)
Characterization of the interaction between muscarinic M2 receptors and beta-adrenoceptor subtypes in guinea-pig isolated ileum. (1995) (12)
Assessing GPCR activation using protein complementation: a novel technique for HTS. (2007) (12)
Agonist action of indole derivatives at 5- HT1 -like, 5-HT2, 5-HT3 and 5-HT4 receptors in vitro (1992) (12)
Characterization of alpha 2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human alpha 2A subtype. (1997) (12)
Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin. (1991) (11)
N-(Quinuclidin-3-yl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide: a high affinity 5-HT3 receptor partial agonist (1995) (11)
Three-Dimensional Cell Culture: A Rapidly Emerging Approach to Cellular Science and Drug Discovery (2017) (11)
[3H]RS 57639, a High Affinity, Selective 5-HT4 Receptor Partial Agonist, Specifically Labels Guinea-pig Striatal and Rat Cloned (5-HT4S and 5-HT4L) Receptors (1997) (11)
High-affinity interactions of ligands at recombinant Guinea pig 5HT7 receptors (2001) (11)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Absorption and brain penetration of a high affinity, highly selective 5-HT2C receptor antagonist, RS-102221. (1998) (11)
Pharmacological characterization of the muscarinic receptors mediating contraction of canine saphenous vein. (1995) (10)
Problems associated with the application of the Cheng-Prusoff relationship to estimate atropine affinity constants using functional tissue responses. (1989) (10)
Interaction of p-F-HHSiD (p-Fluoro-hexahydrosila-difenidol) at muscarinic receptors in guinea-pig trachea (1990) (10)
Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques (1997) (10)
The 5-hydroxytryptamine (5-HT)7 receptor (1994) (9)
Antibody-free method for protein detection on blots using enzyme fragment complementation. (2006) (9)
11 – An Isoform-selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE4) with Anti-inflammatory Properties (1996) (9)
N,N-6-bis-[2-(3,4-dihydroxybenzyl)pyrrolidinyl]hexane, a potent, selective, orally active dopamine analog with hypotensive and diuretic activity☆ (1995) (8)
Quantitative autoradiography demonstrates selective modulation of rat brain regional dopamine (D1 and D2) receptor subtypes after chronic manipulation of dietary salt (1995) (8)
Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor. (1998) (8)
Muscarinic M3 receptors mediate contractions in rabbit, endothelium-denuded aorta in vitro. (1994) (8)
Ionic strength of assay buffers influences antagonist binding affinity estimates at muscarinic M1–M5 cholinoceptors (1999) (8)
Characterization of human recombinant α2A‐adrenoceptors expressed in Chinese hamster lung cells using extracellular acidification rate changes (2000) (8)
Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 1: Target Identification and Lead Optimization (2018) (8)
Multidisciplinary analysis of muscarinic receptors in guinea-pig isolated ileum, atria and uterus in vitro (1992) (8)
Investigation of the 5-hydroxytryptamine receptor mediating the “transient” short-circuit current response in guinea-pig ileal mucosa (1995) (7)
Erratum: A comparison of the potential role of the tetrodotoxin- insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain (Proceedings of the National Academy of Sciences of the United States of America (July 6, 1999) 96:14 (7640-7644)) (1999) (7)
Chronic manipulation of dietary salt modulates renal physiology and kidney dopamine receptor subtypes: functional and autoradiographic studies. (1995) (7)
(R)-3-(6-CHLORO-1-ISOPROPYLBENZIMIDAZOLE-4-CARBOXAMIDO)QUINUCLIDINE : A HIGH AFFINITY LIGAND FOR THE (R)-ZACOPRIDE BINDING SITE (1996) (7)
Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro (1995) (7)
5-Hydroxytryptamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (6)
High Throughput Screening: Myths and Future Realities (1999) (6)
Advances in serotonin receptor research : molecular biology, signal tranduction, and therapeutics (1998) (6)
Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells. (2000) (5)
Functional pharmacological characterization of the muscarinic cholinoceptor-mediated inhibition of adenylyl cyclase in primary cultured human bladder detrusor smooth muscle cells (1999) (5)
Comparison of the positive chronotropic response to 5-hydroxytryptamine with beta-adrenoceptor agonists on the guinea pig atria in vitro. (1989) (5)
Agonist action of indole derivatives at 5-HT1-like, 5-HT3, and 5HT4 receptors in vitro. (1992) (4)
Muscarinic M2 and M3 receptor function in smooth muscle. (1996) (4)
Current trends in high-throughput screening. (2008) (4)
Comparison of Crude Methanolic CDS Extracts from Various Tissues (1999) (4)
High-Throughput Screening Using Label-Free Technologies (2004) (4)
Homogeneous assays for cellular protein degradation using beta-galactosidase complementation: NF-kappaB/IkappaB pathway signaling. (2003) (4)
M3 muscarinic receptors on murine HSDM1C1 cells: Further functional, regulatory, and receptor binding studies (2004) (3)
Acetylcholine receptors (muscarinic) (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (3)
Thepharmacological properties ofthepeptide, endothelin (1989) (3)
RS‐61756‐007: a potent and selective thromboxane receptor (TP) agonist (1989) (3)
A pharmacological comparison of [3H]GBR12935 binding to rodent striatal and kidney homogenates: Binding to dopamine transporters? (1992) (3)
Characterization of muscarinic receptors mediating release of epithelial derived relaxant factor (EpDRF) in guinea-pig isolated trachea (1991) (3)
In Vitro Isolated Tissue Functional Muscarinic Receptor Assays (2010) (3)
Subtypes of muscarinic receptors: the seventh international symposium. (1997) (3)
Monthly Update: Novel imidazoline site ligands: Central & Peripheral Nervous Systems (1995) (2)
Muscarinic M2 receptors modulate relaxant responses to isoproterenol in rat urinary bladder (1997) (2)
The action of (±)L-660,863 [(±)3-(3-amino-1,2,4-oxadiazole-5-yl)-quinuclidine] at muscarinic receptor subtypes in vitro (1992) (2)
Selective modulation of muscarinic receptor subtypes: therapeutic potential (1998) (2)
Desensitization and functional antagonism by β‐adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity (1991) (2)
Identifying orphan G protein coupled receptors in drug discovery. (2004) (2)
N-(Quinuclidin-3-yl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide: A High Affinity 5-HT3 Receptor Partial Agonist. (1995) (2)
Characterization of muscarinic receptors in guinea-pig seminal vesicle (1993) (2)
The Evaluation of a Haemoperfusion Device in Conscious Dogs (1981) (2)
Monthly Update: The (R) zacopride binding site:Central & Peripheral Nervous Systems (1995) (2)
Muscarinic receptor protection studies in isolated, functional preparations (1993) (2)
MUSCARINIC RECEPTOR ANTAGONISTS : PHARMACOLOGICAL AND THERAPEUTIC UTILITY (1998) (2)
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors. (2000) (2)
Local anesthetics and tricyclic antidepressants attenuate mechanical hyperalgesia and allodynia in experimental models of chronic neuropathic pain (1995) (2)
Similarities in antagonist affinity profiles of muscarinic M3 and M5 cholinoceptors: Pharmacological difficulties associated with identifying a functional M5 receptor (1999) (2)
Pharmacological evaluation of 1229U91, a high affinity and selective neuropeptide Y (NPY) - Y1 receptor antagonist (1995) (1)
alpha 2A-adrenoceptors, not I1-imidazoline receptors, mediate the hypotensive effects of rilmenidine and moxonidine in conscious mice. In vivo and in vitro studies. (1999) (1)
Muscarinic receptors in rat uterus: Effect of ovariectomy (1999) (1)
Pharmacological differences between atrial and smooth muscle muscarinic receptors (1986) (1)
Biochemical and Behavioral Pharmacology of RS-102221, a Subtype Selective 5-HT2c Receptor Antagonist (1997) (1)
High‐Throughput GPCR Screening Technologies and the Emerging Importance of the Cell Phenotype (2010) (1)
Preface (1998) (1)
Muscarinic Receptor Assays (2001) (1)
Muscarinic receptor antagonists (2015) (1)
The identification of heterogeneity of 5-HT3 receptors with [3H]RS-42358-197. (1995) (1)
Large-scale expansion of stem cells for therapy and screening (2014) (1)
MUSCARINIC ACETYLCHOLINE RECEPTORS AND CONTROL OF SMOOTH MUSCLE TONE. AUTHORS' REPLY (1994) (1)
Muscarinic receptor crosstalk in the regulation of ERK and JNK activities in CHO-m2m3 cells (2000) (1)
Chapter 11:3D Cell Culture and Dish Based Organogenesis: Optimizing In vitro Cellular Physiology (2016) (1)
Functional roles of postjunctional muscarinic M2 receptors in airway smooth muscle (2001) (1)
Screening the human kinome:Layout 1 (2008) (0)
Meeting Highlights: Central & Peripheral Nervous Systems, Receptor classification: The integration of operational, transductional and structural information September 21–22, 1995, Verona, Italy (1995) (0)
Characterization of novel sodium channels in peripheral sensory neurons (1999) (0)
Effects of enprostil on cardiovascular and respiratory parameters in the dog, and on hematologic parameters in the rat, monkey, and human. (1989) (0)
Characterization of the interaction between muscarinic M2 receptors and 13-adrenoceptor subtypes in guinea-pig isolated ileum (2006) (0)
Nomenclature in the Field of Eicosanoids (1990) (0)
Pharmacological properties of endothelin in vitro. (1989) (0)
Recent advances in angiotensin receptor research (1994) (0)
5-Hydroxytryptamine (5-HT)3 Receptors: Molecular Biology, Pharmacology and Therapeutic Importance (1996) (0)
Characterization of muscarinic receptor subtypes mediating total inositol phosphates (IPS) accumulation in rabbit iris sphincter in vitro (1992) (0)
Novel 1-phenylalkanon 5-HT 4 receptor ligands (1994) (0)
Eglen et al. reply (1994) (0)
Recent Advances in Muscarinic Receptor Pharmacology & Therapeutics (2008) (0)
Acetylcholine receptors (muscarinic) in GtoPdb v.2021.3 (2021) (0)
Current and emerging trends in cell-based assays (2009) (0)
Pharmacological profile of the dopamine (DA) agonists, RS-12254. (1991) (0)
Characterization of human recombinant a2A-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca changes: evidence for cross-talk between recombinant (0)
High throughput screening:Layout 1 (2009) (0)
Characterization of (cid:97) 2 -adrenoceptors mediating contraction of dog saphenous vein: identity with the human (cid:97) 2A subtype (1997) (0)
An interview with Richard M. Eglen, Ph.D. (2006) (0)
Process for the preparation of pharmaceutically useful new one-fenyylialkanoni-5-HT 4 receptor ligands (1995) (0)
PHENOTYPIC SCREENING single-cell analysis versus 3 D multicell analysis (2019) (0)
SLAS LEADERSHIP COMMITTEES AND COUNCILS (2016) (0)
Monthly Update Central & Peripheral Nervous Systems The (R) zacopride binding site (1995) (0)
Interleukin-1 beta induces nerve growth factor release and gene expression in human glioblastoma cells. (1995) (0)
Effect of tryptamine analogues at 5-HT3 and S-HT4 receptors in isolated guinea-pig ileum (1990) (0)
(R)-3-(6-Chloro-1-isopropylbenzimidazole-4-carboxamido)quinuclidine: A High Affinity Ligand for the (R)-Zacopride Binding Site. (1996) (0)
Complex M2/M3 receptor antagonist profile in human colon bioassay (1999) (0)
Monthly Update Central & Peripheral Nervous Systems Muscarinic M2 and M3 receptors in smooth muscle (1995) (0)
Process for the preparation of new therapeutically useful tricyclic, nitrogen-containing compounds (1990) (0)
Homogeneous High-Throughput Screening (HTS) Assays for Serine/Threonine Kinases Using beta-Galactosidase Enzyme Fragment Complementation (2006) (0)
N,N-6-Bis-(2-(3,4-Dihydroxybenzyl)pyrrolidinyl)hexane, a Potent, Selective, Orally Active Dopamine Analogue with Hypotensive and Diuretic Activity. (2010) (0)
Pharmacological evaluation of alpha-1-adrenoceptor agonists for the treatment of urinary stress incontinence (1997) (0)
Colloquium Paper. in the Article " a Comparison of the Po- Tential Role of the Tetrodotoxin-insensitive Sodium Channels, Pn3͞sns and Nan͞sns2, in Rat Models of Chronic Pain " By (1999) (0)
EVALUATION OF THE COGNITIVE ENHANCING EFFECTS OF ONDANSETRON IN THE MORRIS WATER MAZE. (1992) (0)
New tricyclic compound (1990) (0)
Society Updates (2005) (0)
Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2 (2021) (0)
A Homogeneous, Fluorescent Polarization Assay for Inositol 1,4,5-Trisphosphate (Ins P3) (2006) (0)
Convergence of Three-Dimensional Cell Culture and Human iPS Cells: Improving Clinical Relevance in Drug Discovery (2019) (0)
Central & Peripheral Nervous Systems Novel imidazoline site ligands (1995) (0)
Characterisation of the prostanoid receptor profile of 9,10α-epoxy and 9,10β-epoxy prostadienoic acids in vitro (1990) (0)
Pharmacological profile of the dopamine agonist, RS-45946. (1990) (0)
Derivatives of Phenylurea as Antagonists of Mice, Rat, Guinea Pig, and Rabbit 5-HT3 Receptors. (1995) (0)
Antagonist RS-100302 in Experimental Atrial Flutter and Fibrillation Receptor 4 Electrophysiological and Antiarrhythmic Effects of the Atrial Selective 5-HT (1999) (0)

This paper list is powered by the following services:

Richard M. Eglen's Academic­Influence.com Rankings

Why Is Richard M. Eglen Influential?

Richard M. Eglen's Published Works

Published Works

Richard M. Eglen's AcademicInfluence.com Rankings